How Investors Are Reacting To Merck (MRK) Phase 3 Melanoma Results

Merck & Co., Inc. is preparing to present Phase 3 melanoma data for its personalized cancer treatment with Moderna, alongside progress in its KRAS inhibitor program, including MK-1084, which previously received Breakthrough Therapy Designation for first line advanced NSCLC with KRAS G12C mutations. The combination of late stage melanoma data with Keytruda and an advancing KRAS pipeline highlights how Merck is trying to broaden its oncology revenue base beyond any single product. We will now...